■髂静脉压迫综合征(IVCS)是静脉手术后静脉曲张(VV)复发的根本原因。然而,复发性静脉曲张(RVV)合并IVCS的治疗很少有报道.这项研究旨在调查一站式手术的结果,以纠正RVV和IVCS患者的流出道阻塞和表面反流。
■对102例诊断为RVV的连续患者进行了回顾性分析。进行计算机断层扫描静脉造影(CTV)以确认IVCS。将病例分为两组:IRVV组,包括RVV和IVCS患者(n=48),和RVV组,包括仅有RVV的患者(n=54)。的特点,静脉反流,临床,病因学,解剖学,和病理生理(CEAP)分布进行了调查。然后,将接受腔内激光消融(EVLA)(n=39)的IRVVs组患者分为2组:EVLAS组(n=19),谁接受了EVLA和髂静脉支架术,和EVLA组(n=20),他们单独接受EVLA治疗。大隐/小隐静脉(GSV/SSV)主干闭塞,VV复发,视觉模拟量表(VAS),和静脉临床严重程度评分(VCSS)进行调查。
■IRVVs组股静脉反流发生率为81.2%,RVVs组股静脉反流发生率为50%(P<0.05)。在IRVV组中,72.9%的患者表现为CEAP临床分类>3级,高于RVVs组的48.1%(P<0.05)。EVLA+S组和EVLA组12个月GSV/SSV闭塞率分别为94.7%和90.0%,分别。EVLA+S组9例,EVLA组6例出现活动性静脉溃疡,EVLA+S组溃疡愈合时间明显缩短(27.22±7.12vs.46.67±9.83天,P<0.05)。基线之间的VAS和VCSS值的减少,1个月,EVLA+S组12个月明显优于EVLA组(P<0.05)。
■对RVV和IVCS患者进行髂静脉支架和EVLA的一站式联合治疗是安全有效的,并提供了显着的症状缓解,提高生活质量,溃疡愈合比单独EVLA更令人满意。
UNASSIGNED: Iliac vein compression syndrome (IVCS) is an underlying cause of varicose vein (VV) recurrence after venous surgery. However, the management of recurrent varicose veins (RVVs) combined with IVCS has rarely been reported. This study aimed to investigate the outcomes of a one-stop procedure to correct outflow obstruction and superficial reflux for patients with RVVs and IVCS.
UNASSIGNED: A retrospective analysis was conducted of 102 consecutive patients diagnosed with RVVs. Computed tomography venography (CTV) was performed to confirm IVCS. The cases were divided into 2 groups: the IRVVs group, including patients with RVVs and IVCS (n=48), and the RVVs group, including patients with RVVs only (n=54). The characteristics, vein reflux, and clinical, etiological, anatomical, and pathophysiological (CEAP) distribution were investigated. Then, the IRVVs group patients who underwent endovenous laser ablation (EVLA) (n=39) were divided into a further 2 groups: the EVLA + S group (n=19), who received EVLA and stenting of iliac vein, and the EVLA group (n=20), who received EVLA treatment alone. The great/small saphenous vein (GSV/SSV) trunk occlusion, VV recurrence, visual analogue scale (VAS), and venous clinical severity score (VCSS) were investigated.
UNASSIGNED: The prevalence rate of femoral vein reflux was 81.2% in IRVVs group and 50% in RVVs group (P<0.05). In the IRVVs group, 72.9% of patients manifested as CEAP clinical class >3, which was higher than that in RVVs group (48.1%) (P<0.05). The 12-month GSV/SSV occlusion rate in the EVLA + S and EVLA groups were 94.7% and 90.0%, respectively. Totals of 9 patients in EVLA + S group and 6 patients in EVLA group had active venous ulcers, and the ulcer healing time in EVLA + S group was significantly shorter (27.22±7.12 vs. 46.67±9.83 days, P<0.05). The reductions in the VAS and VCSS values between baseline, 1 month, and 12 months in the EVLA + S group were more obvious than those in EVLA group (P<0.05).
UNASSIGNED: The one-stop combination treatment of iliac venous stenting and EVLA in patients with RVVs and IVCS is safe and effective and provides prominent symptom relief, improved quality of life, and a more satisfactory ulcer healing than EVLA alone.